"ADAMTS13 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An ADAMTS protease that contains eight thrombospondin (TS) motifs. It cleaves VON WILLEBRAND FACTOR to control vWF-mediated THROMBOSIS. Mutations in the ADAMTS13 gene have been identified in familial cases of PURPURA, THROMBOTIC THROMBOCYTOPENIC and defects in ADAMTS13 activity are associated with MYOCARDIAL INFARCTION; BRAIN ISCHEMIA; PRE-ECLAMPSIA; and MALARIA.
| Descriptor ID |
D000071120
|
| MeSH Number(s) |
D08.811.277.656.675.374.102.500.813 D09.400.430.500.500.813 D12.776.395.033.500.813 D12.776.860.300.085.813
|
| Concept/Terms |
ADAMTS13 Protein- ADAMTS13 Protein
- von Willebrand Factor-Cleaving Protease
- von Willebrand Factor Cleaving Protease
- ADAMTS13 Protease
- vWF-Cleaving Protease
- vWF Cleaving Protease
- ADAMTS-13 Protein
- ADAMTS 13 Protein
- A Disintegrin and Metalloproteinase with Thrombospondin Motifs 13 Protein
|
Below are MeSH descriptors whose meaning is more general than "ADAMTS13 Protein".
Below are MeSH descriptors whose meaning is more specific than "ADAMTS13 Protein".
This graph shows the total number of publications written about "ADAMTS13 Protein" by people in this website by year, and whether "ADAMTS13 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "ADAMTS13 Protein" by people in Profiles.
-
Hereditary thrombotic thrombocytopenic purpura acquired through liver transplantation: A case report. Am J Transplant. 2023 03; 23(3):437-439.
-
Implementation of a rapid assay of ADAMTS13 activity was associated with improved 30-day survival rate in patients with acquired primary thrombotic thrombocytopenic purpura who received platelet transfusions. Transfusion. 2017 08; 57(8):2045-2053.
-
Thrombotic thrombocytopenic purpura: gaining knowledge. Lancet Haematol. 2016 05; 3(5):e210-1.
-
Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting: visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma. Transfusion. 2015 Oct; 55(10):2321-30.
-
Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR). Br J Haematol. 2013 Jun; 161(6):896-8.
-
Acquired idiopathic ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in a population from Japan. PLoS One. 2012; 7(3):e33029.
-
Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura. Haematologica. 2010 Sep; 95(9):1555-62.
-
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008). Kidney Int Suppl. 2009 Feb; (112):S20-4.
-
Drug-induced thrombotic microangiopathy. Semin Thromb Hemost. 2005 Dec; 31(6):681-90.
-
Thrombotic thrombocytopenic purpura-2005. Semin Thromb Hemost. 2005 Dec; 31(6):611-4.